---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-23-000012"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:17:55.300158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)

## Summary
- Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).
- Full-year 2022 net revenue $499.0M vs $437.8M, GAAP net income $91.4M ($1.74) vs $62.1M ($1.25).
- Adjusted non-GAAP Q4 EPS $0.73, full-year $1.97; growth driven by epinephrine, Primatene MIST, and glucagon.
- CEO cites strongest quarter and anticipates multiple new product launches in 2023.
- No forward guidance provided; financial comparisons are to prior-year periods.

## SEC filing metadata
- accession: 0001297184-23-000012
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/amph-20230228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-23-000012
- JSON: https://secwatch.observer/filing/0001297184-23-000012.json
- Plain text: https://secwatch.observer/filing/0001297184-23-000012.txt

## Key facts
- Earnings Releases
  Amphastar Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2022 results: revenue $499.0 million, net income $91.4 million, EPS $1.74 per share.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $499.0 million
  - Net income: $91.4 million
  - EPS: $1.74 per share
  - Result: reported results
  source text: Net revenues of $499.0 million for the fiscal year ● GAAP net income of $91.4 million, or $1.74 per share, for the fiscal year ● Adjusted non-GAAP net income of $103.2 million, or $1.97 per share, for the fiscal year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm
- Earnings Releases
  Amphastar Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: revenue $135.0 million, net income $33.9 million, EPS $0.66 per share.
  - Period: the three months ended December 31, 2022
  - Revenue: $135.0 million
  - Net income: $33.9 million
  - EPS: $0.66 per share
  - Result: reported results
  source text: Net revenues of $135.0 million for the fourth quarter ● GAAP net income of $33.9 million, or $0.66 per share, for the fourth quarter ● Adjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.